Epstein–barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection

Frontiers in Microbiology

Volumn 4, Issue , 2013, Pages

  Petrara, Maria R ^a   Freguja, Riccardo ^a   Gianesin, Ketty ^a   Zanchetta, Marisa ^b   De Rossi, Anita ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Antiretroviral therapy; B cell activation; Chronic immune activation; EBV; EBV lytic reactivation; EBV related malignancies; HIV 1

Indexed keywords

ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; CD27 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HEPARAN SULFATE; HLA DR ANTIGEN; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; LIPOPOLYSACCHARIDE; MITOCHONDRIAL DNA; NEF PROTEIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PROTEIN BCL 2; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANGIOGENESIS; ANTIRETROVIRAL THERAPY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BURKITT LYMPHOMA; CARCINOGENESIS; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STIMULATION; DISEASE EXACERBATION; DOWN REGULATION; EPSTEIN BARR VIRUS; HEPATITIS B; HEPATITIS C; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOBLASTIC LYMPHOMA; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOSURVEILLANCE; INCIDENCE; MACROPHAGE; MAPK SIGNALING; NATURAL KILLER CELL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROTEIN EXPRESSION; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; VIREMIA; VIRUS DETECTION; VIRUS GENOME; VIRUS LOAD;

EID: 84900447559     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2013.00311     Document Type: Review

References (78)

1. Ambinder, R. F., Bhatia, K., Martinez-Maza, O., and Mitsuyasu, R. (2010). Cancer biomarkers in HIV patients. Curr. Opin. HIV AIDS 5, 531–536. doi: 10.1097/COH. 0b013e32833f327e
2. Anselmi, A., Vendrame, D., Rampon, O., Giaquinto, C., Zanchetta, M., and De Rossi, A. (2007). Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clin. Exp. Immunol. 150, 442–450. doi: 10.1111/j.1365-2249.2007.03526.x
3. Audigé, A., Schlaepfer, E., von Wyl, V., Miller, R. C., Vernazza, P., Nadal, D., et al. (2010). B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-α response to TLR9 triggering. AIDS Res. Hum. Retroviruses 26, 1063–1074. doi: 10.1089/aid.2009.0288
4. Baiocchi, R. A., and Caligiuri, M. A. (1994). Low-dose interleukin 2 prevents the development of Epstein– Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 91, 5577–5581. doi: 10.1073/pnas.91.12.5577
5. Beral, V., and Newton, R. (1998). Overview of the epidemiology of immunodeficiency-associated cancers. J. Natl. Cancer Inst. Monogr. 23, 1–6. doi: 10.1093/oxfordjour-nals.jncimonographs.a024164
6. Berberian, L., Goodglick, L., Kipps, T. J., and Braun, J. (1993). Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 261, 1588–1591. doi: 10.1126/sci-ence.7690497
7. Biggar, R. J., Chaturvedi, A. K., Goedert, J. J., and Engels, E. A.; HIV/AIDS Cancer Match Study. (2007). AIDS-related cancer and severity of immunosuppression in persons with AIDS. J. Natl. Cancer Inst. 99, 962– 972. doi: 10.1093/jnci/djm010
8. Blackburn, E. H., Greider, C. W., and Szostak, J. W. (2006). Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat. Med. 12, 1133–1138. doi: 10.1038/nm1006-1133
9. Blazevic, V., Heino, M., Lagerstedt, A., Ranki, A., and Krohn, K. J. (1996). Interleukin-10 gene expression induced by HIV-1 Tat and Rev in the cells of HIV-1 infected individuals. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13, 208–214. doi: 10.1097/00042560-199611010-00002
10. Breen, E. C., Hussain, S. K., Magpantay, L., Jacobson, L. P., Detels, R., Rabkin, C. S., et al. (2011). B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol. Biomarkers Prev. 20, 1303–13014. doi: 10.1158/1055-9965.EPI-11-0037
11. Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., et al. (2006). Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365–1371. doi: 10.1038/nm1511
12. Burighel, N., Ghezzi, S., Nozza, S., Del Bianco, P., Lazzarin, A., Tam-bussi, G., et al. (2006). Differential dynamics of Epstein–Barr virus in HIV-1 infected individuals receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica 91, 244–247.
13. Carbone, A., Cesarman, E., Spina, M., Gloghini, A., and Schulz, T. F. (2009). HIV-associated lymphomas and gamma-herpesviruses. Blood 113, 1213–1224. doi: 10.1182/blood-2008-09-180315
14. Cattelan, A. M., Calabrò, M. L., Aversa, M. L., Zanchetta, M., Meneghetti, F., De Rossi, A., et al. (1999). Regression of AIDS-related Kaposi’s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur. J. Cancer 35, 1809–1815. doi: 10.1016/S0959-8049(99)00161-6
15. Chen, M. R. (2011). Epstein–Barr virus, the immune system, and associated diseases. Front. Microbiol. 2:5. doi: 10.3389/fmicb.2011.00005
16. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. (2009). Incidence and risk factors of HIV-related non-Hodgkin’s lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir. Ther. 14, 1065–1074. doi: 10.3851/IMP1462
17. Colombrino, E., Rossi, E., Ballon, G., Terrin, L., Indraccolo, S., Chieco-Bianchi, L., et al. (2004). Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein– Barr virus-immortalized B cells. Exp. Cell Res. 295, 539–548. doi: 10.1016/j.yexcr.2004.01.018
18. Deeken, J. F., Tjen-A-Looi, A., Rudek, M. A., Okuliar, C., Young, M., Little, R. F., et al. (2012). The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin. Infect. Dis. 55, 1228–1235. doi: 10.1093/cid/cis613
19. + T-cell changes independent of viral load. Blood 104, 942–947. doi: 10.1182/blood-2003-09-3333
20. De Rossi, A., Ometto, L., Ron-cella, S., D’Andrea, E., Menin, C., Calderazzo, F., et al. (1994). HIV-1 induces down-regulation of bcl-2 expression and death by apoptosis of EBV-immortalized B cells: a model for a persistent “self-limiting” infection. Virology 198, 234–244. doi: 10.1006/viro.1994.1026
21. Dolcetti, R., and De Rossi, A. (2012). Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis:pathogenetic and clinical implications. Med. Res. Rev. 32, 233–253. doi: 10.1002/med.20211
22. Draborg, A. H., Duus, K., and Houen, G. (2012). Epstein–Barr virus and systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 370516. doi: 10.1155/2012/370516
23. Engels, E. A., Pfeiffer, R. M., Land-gren, O., and Moore, R. D. (2010). Immunologic and virologic predic-tors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J. Acquir. Immune Defic. Syndr. 54, 78–84. doi: 10.1097/01.qai.0000371677.48743.8d
24. Franceschi, S., Lise, M., Clifford, G. M., Rickenbach, M., Levi, F., Maspoli, M., et al. (2010). Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br. J. Cancer 103, 416–422. doi: 10.1038/sj.bjc.6605756
25. Frankel, A. D., and Pabo, C. O. (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189–1193. doi: 10.1016/0092-8674(88)90263-2
26. Giunco, S., Dolcetti, R., Keppel, S., Celeghin, A., Indraccolo, S., Dal Col, J., et al. (2013). hTERT inhibition triggers Epstein–Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies. Clin. Cancer Res. 19, 2036– 2047. doi: 10.1158/1078-0432.CCR-12-2537
27. Goedert, J. J., Coté, T. R., Virgo, P., Scoppa, S. M., Kingma, D. W., Gail, M. H., et al. (1998). Spectrum of AIDS-associated malignant disorders. Lancet 351, 1833–1839. doi: 10.1016/S0140-6736(97)09028-4
28. Gougeon, M. L., Lecoeur, H., Dulioust, A., Enouf, M. G., Crouvoiser, M., Goujard, C., et al. (1996). Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J. Immunol. 156, 3509–3520.
29. Grulich, A. E. (2009). Living longer with HIV: what does it mean for cancer risk? Curr. Opin. HIV AIDS 4, 1–2. doi: 10.1097/COH. 0b013e32831c508a
30. Grulich, A. E., Wan, X., Law, M. G., Mil-liken, S. T., Lewis, C. R., Garsia, R. J., et al. (2000). B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin’s lymphoma in people with AIDS. AIDS 14, 133–140. doi: 10.1097/00002030-200001280-00008
31. Guiguet, M., Boué, F., Cadranel, J., Lang, J. M., Rosenthal, E., Costagli-ola, D., et al. (2009). Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 10, 1152– 1159. doi: 10.1016/S1470-2045(09) 70282-7
32. Hazenberg, M. D., Stuart, J. W., Otto, S. A., Borleffs, J. C., Boucher, C. A., de Boer, R. J., et al. (2000). T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95, 249–255.
33. He, B., Qiao, X., Klasse, P. J., Chiu, A., Chadburn, A., Knowles, D. M., et al. (2006). HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J. Immunol. 176, 3931–3941.
34. Hellerstein, M. K., Hoh, R. A., Han-ley, M. B., Cesar, D., Lee, D., Neese, R. A., et al. (2003). Subpop-ulations of long-lived and short-lived T cells in advanced HIV-1 infection. J. Clin. Invest. 112, 956–966. doi: 10.1172/JCI17533
35. Hong, G. K., Kumar, P., Wang, L., Damania, B., Gulley, M. L., Delecluse, H. J., et al. (2005). Epstein–Barr virus lytic infection is required for efficient production of the angio-genesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J. Virol. 79, 13984–13992. doi: 10.1128/JVI.79.22.13984-13992. 2005
36. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197, 126–133. doi: 10.1086/524143
37. International Collaboration on HIV and Cancer. (2000). Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl. Cancer Inst. 92, 1823–1830. doi: 10.1093/jnci/92.22.1823
38. Iyengar, S., and Schwartz, D. H. (2011). Potentiation of EBV-induced B cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis. AIDS Res. Hum. Retroviruses 27, 519–523. doi: 10.1089/aid.2010.0131
39. Jacobson, C. A., and Abramson, J. S. (2012). HIV-associated Hodgkin’s lymphoma: prognosis and therapy in the era of cART. Adv. Hematol. 2012, 507257. doi: 10.1155/2012/507257
40. Jacobson, L. E., Pilaro, F., and Smith, K. A. (1996). Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. U.S.A. 93, 10405– 10410. doi: 10.1073/pnas.93.19. 10405
41. Janeway, C. A. Jr., and Medzhi-tov, R. (2002). Innate immune recognition. Annu. Rev. Immunol. 20, 197–216. doi: 10.1146/annurev. immunol.20.083001.084359
42. Kaplan, L. D. (2012). HIV-associated lymphoma. Best Pract. Res. Clin. Haematol. 25, 101–117. doi: 10.1016/j.beha.2012.01.001
43. Ladell, K., Dorner, M., Zauner, L., Berger, C., Zucol, F., Bernasconi, M., et al. (2007). Immune activation suppresses initiation of lytic Epstein– Barr virus infection. Cell. Microbiol. 9, 2055–2069. doi: 10.1111/j.1462-5822.2007.00937.x
44. Lazzi, S., Bellan, C., De Falco, G., Cinti, C., Ferrari, F., Nyongo, A., et al. (2002). Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin’s lymphomas: implications for disease pathogenesis. Hum. Pathol. 33, 723–731. doi: 10.1053/hupa.2002.125372
45. Ma, S. D., Hegde, S., Young, K. H., Sullivan, R., Rajesh, D., Zhou, Y., et al. (2011). A new model of Epstein– Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J. Virol. 85, 165–177. doi: 10.1128/JVI.01512-10
46. Malaspina, A., Moir, S., Ho, J., Wang, W., Howell, M. L., O’Shea, M. A., et al. (2006). Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc. Natl. Acad. Sci. U.S.A. 103, 2262–2267. doi: 10.1073/pnas.0511094103
47. + T cells and circulating in plasma. J. Virol. 76, 8855– 8863. doi: 10.1128/JVI.76.17.8855-8863.2002
48. Malnati, M., Broccolo, F., Nozza, S., Sarmati, L., Ghezzi, S., Locatelli, G., et al. (2002). Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. Blood 100, 1575–1578.
49. Mandl, J. N., Barry, A. P., Vander-ford, T. H., Kozyr, N., Chavan, R., Klucking, S., et al. (2008). Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14, 1077–1087. doi: 10.1038/nm.1871
50. Marks, M. A., Rabkin, C. S., Engels, E. A., Busch, E., Kopp, W., Rager, H., et al. (2013). Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS 27, 469–474. doi: 10.1097/QAD. 0b013e32835c1333
51. Moir, S., and Fauci, A. S. (2009). B cells in HIV infection and disease. Nat. Rev. Immunol. 9, 235–245. doi: 10.1038/nri2524
52. Moir, S., Malaspina, A., Li, Y., Chun, T. W., Lowe, T., Adelsberger, J., et al. (2000). B cells of HIV-1-infected patients bind virions through CD21 complement interactions and transmit infectious virus to activated T cells. J. Exp. Med. 192, 637–646. doi: 10.1084/jem.192.5.637
53. Ometto, L., Menin, C., Masiero, S., Bonaldi, L., Del Mistro, A., Cattelan, A. M., et al. (1997). Molecular profile of Epstein–Barr virus (EBV) in human immunodeficiency virus type 1 (HIV-1)-related lymphadenopathies and lymphomas. Blood 90, 313–322.
54. Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853–860. doi: 10.1056/NEJM199803263381301
55. Petoumenos, K., van Leuwen, M. T., Vajdic, C. M., Woolley, I., Chuah, J., Templeton, D. J., et al. (2013). Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Med. 14, 77–84. doi: 10.1111/j.1468-1293.2012.01038.x
56. Petrara, M. R., Cattelan, A. M., Zanchetta, M., Sasset, L., Freguja, R., Gianesin, K., et al. (2012). Epstein–Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J. Clin. Virol. 53, 195–200. doi: 10.1016/j.jcv.2011.12.013
57. Powles, T., Robinson, D., Stebbing, J., Shamash, J., Nelson, M., Gaz-zard, B., et al. (2009). Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol. 27, 884–890. doi: 10.1200/JCO.2008.19.6626
58. Qiao, X., He, B., Chiu, A., Knowles, D. M., Chadburn, A., and Cerutti, A. (2006). Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat. Immunol. 7, 302–310. doi: 10.1038/ni1302
59. Rappocciolo, G., Piazza, P., Fuller, C. L., Reinhart, T. A., Watkins, S. C., Rowe, D. T., et al. (2006). DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog. 2:e70. doi: 10.1371/journal.ppat.0020070
60. Regidor, D. L., Detels, R., Breen, E. C., Widney, D. P., Jacobson, L. P., Palella, F., et al. (2011). Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 25, 303– 314. doi: 10.1097/QAD.0b013e3283 4273ad
61. Rieckmann, P., Poli, G., Fox, C. H., Kehrl, J. H., and Fauci, A. S. (1991). Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronega-tive donors. J. Immunol. 147, 2922– 2927.
62. Righetti, E., Ballon, G., Ometto, L., Cattelan, A. M., Menin, C., Zanchetta, M., et al. (2002). Dynamics of Epstein–Barr virus in human immunodeficiency virus type 1-infected subjects on highly active antiretroviral therapy. AIDS 16, 63–73. doi: 10.1097/00002030-200201040-00009
63. Scaffidi, P., Misteli, T., and Bianchi, M. E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195. doi: 10.1038/nature00858
64. Scala, G., Ruocco, M. R., Ambrosino, C., Mallardo, M., Giordano, V., Baldassarre, F., et al. (1994). The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J. Exp. Med. 179, 961–971. doi: 10.1084/jem.179.3.961
65. Schnittman, S. M., Lane, H. C., Higgins, S. E., Folks, T., and Fauci, A. S. (1986). Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science 233, 1084–1086. doi: 10.1126/science.3016902
66. Simard, E. P., Pfeiffer, R. M., and Engels, E. A. (2011). Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 117, 1089–1096. doi: 10.1002/cncr.25547
67. Sørensen, O. E., Thapa, D. R., Rosenthal, A., Liu, L., Roberts, A. A., and Ganz, T. (2005). Differential regulation of beta-defensin expression in human skin by microbial stimuli. J. Immunol. 174, 4870– 4879.
68. Sparano, J. A. (2001). Clinical aspects and management of AIDS-related lymphomas. Eur. J. Cancer 37, 1296–1305. doi: 10.1016/S0959-8049(01)00111-3
69. Swingler, S., Zhou, J., Swingler, C., Dauphin, A., Greenough, T., Joli-coeur, P., et al. (2008). Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe 4, 63–76. doi: 10.1016/j.chom.2008. 05.015
70. Takeshita, S., Breen, E. C., Ivashchenko, M., Nishanian, P. G., Kishi-moto, T., Vredevoe, D. L., et al. (1995). Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocytic cell line. Cell. Immunol. 165, 234–242. doi: 10.1006/cimm.1995.1210
71. Terrin, L., Dal Col, J., Rampazzo, E., Zancai, P., Pedrotti, M., Ammirabile, G., et al. (2008). Latent membrane protein 1 of Epstein–Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J. Virol. 82, 10175– 10187. doi: 10.1128/JVI.00321-08
72. Terrin, L., Dolcetti, R., Corradini, I., Indraccolo, S., Dal Col, J., Bertorelle, R., et al. (2007). hTERT inhibits the Epstein–Barr virus (EBV) lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis. Int. J. Cancer 121, 576–587. doi: 10.1002/ijc.22661
73. Tirelli, U., and Bernardi, D. (2001). Impact of HAART on the clinical management of AIDS-related cancers. Eur. J. Cancer 37, 1320– 1324. doi: 10.1016/S0959-8049(01) 00106-X
74. Titanji, K., De Milito, A., Cagigi, A., Thorstensson, R., Grützmeier, S., Atlas, A., et al. (2006). Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108, 1580– 1587. doi: 10.1182/blood-2005-11-013383
75. Tyagi, M., Rusnati, M., Presta, M., and Giacca, M. (2001). Internaliza-tion of HIV-1 Tat requires cell surface heparan sulphate proteoglycans. J. Biol. Chem. 276, 3254–3256. doi: 10.1074/jbc.M006701200
76. Young, L. S., and Rickinson, A. B. (2004). Epstein–Barr virus: 40 years on. Nat. Rev. Cancer 4, 757–768. doi: 10.1038/nrc1452
77. Zauner, L., and Nadal, D. (2012). Understanding TLR9 action in Epstein–Barr virus infection. Front. Biosci. (Landmark Ed.) 17: 1219–1231. doi: 10.2741/3982
78. Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., et al. (2010). Circulating mito-chondrial DAMPs cause inflammatory responses to injury. Nature 464, 104–107. doi: 10.1038/nature 08780